Director, US Strategic Pricing, Pipeline

Revolution Medicines•Redwood City, CA

8h•$211,000 - $264,000•Hybrid

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Director, US Strategic Pricing to lead lifecycle price recommendations for portfolio assets including pipeline price strategies, gross-to-net and forecast inputs, as well as market access tactics with USMA colleagues, brand and finance stakeholders to maximize brand and portfolio corporate value. The Director, US Strategic Pricing will serve as a subject matter expert in US Market Access and Oncology price strategy with deep knowledge of mandated and commercial payer environments, US pricing policy and global pricing interdependences. The Director will report to the Senior Director, US Strategic Pricing and will serve in a critical function to shape list and net pricing recommendations and strategies as the company grows as a commercial organization. This role will work closely with US and Global Market Access and Commercial leadership, Finance, US and Global Forecasting as well as broader Commercial and Medical organizations. This role can be based in Redwood City, CA location or can be remotely based with up to 15% travel.

Requirements

Bachelor’s degree.
Minimum of 8 years of pharmaceutical market access experience.
2+ years of Oncology product experience.
6+ years pricing, and payer/provider contracting experience to support mandated and discretionary price strategies.
Extensive experience and demonstrated success in customer segment contract strategy, market knowledge, and pricing policies to support products and/or portfolio.
Strong understanding relationship within IRA policy guidelines and CMS price demonstrations.
Experience with day-to-day management of vendor partners.
Strong knowledge of trends, issues and policies influencing drug pricing and oncology market.
Ability to communicate effectively, both orally and in writing.
Ability to effectively deliver strategy and price recommendations and presentations to a variety of audience types across all levels of the organization with impact.
Embrace cross-functional collaboration with internal and external customers; possesses interpersonal skills to develop and maintain cooperative working and business relationships.
Ability to effectively resolve conflicts and multi-department alignment to delivery commercial goals and objectives.

Nice To Haves

Experience with oral oncology therapies and targeted treatments for RAS-mutated cancers.
Advanced degree (MBA, MPH, or similar).

Responsibilities

Develop and lead life cycle list and net price recommendations for pipeline portfolio and indication sequencing pricing strategies.
Effectively partner with internal stakeholders to develop relationships to drive price strategy access including Global Market Access, Pricing, and Development, US Market Access Marketing, Field Key Account teams.
Monitor, assess and recommend pricing adjustments to support life cycle management efforts consistent with pipeline indication expansion opportunities.
Develop contract strategies and structures in close collaboration with USMA, brand and legal partners.
Ensure compliance with all applicable laws, regulations, and company policies related to pricing and contracting.